Exelixis, Inc. (EXEL)

Listed in the US · Manufacturing · Biological products, (no diagnostic substances)

$66.20

As of 29 Oct 2026 close.

Facts from reported results and exchange filings. Not investment advice.

Share price

Prices load here as you scroll to them.

Last close $66.20 on 29 Oct 2026. The share price traded between $36.00 and $67.52 (intraday) over the last 12 months.

The closes as a table

DateClose

Key figures

1-year range (intraday)

Last close $66.20

Low $36.00High $67.52

Market cap$16.4Blast close × shares
P/E20.9on reported profit, last four quarters
Net profit$861Mlast 12 months
Return on equity36.2%year to Jan 2026
EBITDA margin38.8%year to Jan 2026
Debt to equity0.00year to Jan 2026
Net margin33.7%year to Jan 2026
Dividend yieldnonelast 12 months

Price trend

Revenue and profit

RevenueNet profit$ million
01,0002,0003,000
YearDec 2021Dec 2022Dec 2023Jan 2025Jan 2026
Revenue1,4351,6111,8302,1692,320
Net profit231182208521783
EBITDA margin20.9%13.8%10.7%29.2%38.8%
Borrowings00000

$ million. Over three years, compounded: revenue grew 12.9% a year, net profit grew 62.5% a year.

Recent filings

Questions about Exelixis, Inc.

What is Exelixis, Inc.'s market value?

Exelixis, Inc.'s market value is $16.4B as of 29 Oct 2026 close: the last close times the shares in issue. Its P/E is 20.9, the last close over earnings per share for the last four reported quarters.

Go further with EXEL

Free to start: test a trading idea on EXEL's real prices after costs, or open the full deep dive with ten years of numbers, red flags and management's record.

Same industry

The largest companies in the same industry (Biological products, (no diagnostic substances)), by market value.

Browse companies

The companies before and after this one, A to Z, and the lists it is in.

How these figures are worked out

The net profit for the last 12 months is the four latest reported quarters, so it can differ from the newest year's in the table below.